Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anders C. Larsen"'
Autor:
Julia Oto, Silvia Navarro, Anders C. Larsen, María José Solmoirago, Emma Plana, David Hervás, Álvaro Fernández-Pardo, Francisco España, Søren R. Kristensen, Ole Thorlacius-Ussing, Pilar Medina
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 3, p 840 (2020)
Cancer-associated venous thrombosis (VTE) increases mortality and morbidity. However, limited tools are available to identify high risk patients. Upon activation, neutrophils release their content through different mechanisms, thereby prompting throm
Externí odkaz:
https://doaj.org/article/2b710220342d46b28ac4a55f8122d4f2
Autor:
Benjamin E. Stubbe, Poul H. Madsen, Anders C. Larsen, Henrik B. Krarup, Inge S. Pedersen, Carsten P. Hansen, Julia S. Johansen, Stine D. Henriksen, Ole Thorlacius-Ussing
Publikováno v:
Stubbe, B 2023, ' Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma ', Pancreatology . https://doi.org/10.1016/j.pan.2023.05.003
Stubbe, B, Madsen, P H, Larsen, A C, Krarup, H B, Pedersen, I S, Johansen, J S, Henriksen, S D & Thorlacius-Ussing, O 2023, ' Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma ', Pancreatology . https://doi.org/10.1016/j.pan.2023.05.003
Stubbe, B, Madsen, P H, Larsen, A C, Krarup, H B, Pedersen, I S, Johansen, J S, Henriksen, S D & Thorlacius-Ussing, O 2023, ' Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma ', Pancreatology . https://doi.org/10.1016/j.pan.2023.05.003
BackgroundPancreatic ductal adenocarcinoma remains one of the major causes of cancer-related mortality globally. Unfortunately, current prognostic biomarkers are limited, and no predictive biomarkers exist. This study examined promoter hypermethylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de3cee6e3a023423872c6cc41de9e45c
https://vbn.aau.dk/da/publications/a5db5b62-6897-44f8-b46c-67413b030d2c
https://vbn.aau.dk/da/publications/a5db5b62-6897-44f8-b46c-67413b030d2c
Autor:
Benjamin E. Stubbe, Stine D. Henriksen, Poul H. Madsen, Anders C. Larsen, Henrik B. Krarup, Inge S. Pedersen, Julia S. Johansen, Carsten P. Hansen, Ole Thorlacius-Ussing
Publikováno v:
Cancer Research. 82:B047-B047
Background: Pancreatic ductal adenocarcinoma (PDAC) is a disease with an abysmal prognosis. Unfortunately, no reliable prognostic or predictive blood-based biomarkers are currently available. An increasingly promising prognostic and predictive tool i